Figure 3.

SBP-101 treatment results in a decrease in intracellular polyamine content. Lung, pancreatic, and ovarian adenocarcinoma lines were treated with 10 μM of either BENSpm or SBP-101 for 24 h. Cells were then collected and analyzed by HPLC for intracellular polyamine content. Both BENSpm and SBP-101 reduced intracellular putrescine levels to under 25% of original levels in all cell lines, except BxPC-3 (A). Both analogues reduced spermidine content by at least 50% in all treated cell lines, with lung lines showing the most reduction and pancreatic lines showing the least (B). BENSpm treatment decreased spermine levels in all cell lines but with varied intensity. While SBP-101 showed little reduction in spermine levels across the tested cell lines, overall polyamine levels decreased with treatment (C,D).